BMX and cardiomyopathy: Data from the bmx mouse presented here demonstrate that even if dystrophin restoration from exon skipping treatment achieves 100% efficacy, the resultant ‘Becker‐like’ dystrophin may be expressed at lower‐than‐normal levels in muscle due to other factors, and therefore pathology including muscle damage, inflammation, weakness and cardiomyopathy will persist.